The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Haematologica
Prif Awduron: Tarantelli, Chiara, Zhang, Lu, Curti, Elisabetta, Gaudio, Eugenio, Spriano, Filippo, Priebe, Valdemar, Cascione, Luciano, Arribas, Alberto J., Zucca, Emanuele, Rossi, Davide, Stathis, Anastasios, Bertoni, Francesco
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Ferrata Storti Foundation 2019
Pynciau:
Online Only Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6601092/
https://ncbi.nlm.nih.gov/pubmed/30679329
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.214759
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg